Author

M. S. Davids

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Cavalli· 1 shared A. Dutta· 1 shared A. J. Arribas· 1 shared A. Rinaldi· 1 shared A. Stathis· 1 shared B. Berrios· 1 shared C. J. Herbaux· 1 shared C. Sloss· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cavalli

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

A. J. Arribas, E. Gaudio, S. Napoli, C. J. Herbaux, C. Tarantelli, R. Bordone Pittau, L. Cascione, N. Munz, L. Aresu, J. Sgrignani, A. Rinaldi, I. Kwee, D. Rossi, A. Cavalli, E. Zucca, , F. Bertoni

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

bioRxiv · Nov 14, 2023 · PreprintCancer Biology

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

R. Sklavenitis-Pistofidis, E. D. Lightbody, M. Reidy, J. Tsuji, M. P. Aranha, D. Heilpern-Mallory, D. Huynh, S. J. F. Chong, L. Hackett, N. J. Haradhvala, T. Wu, N. K. Su, B. Berrios, J.-B. Alberge, A. Dutta, , S. Manier

bioRxiv · Aug 1, 2023 · PreprintCancer Biology

Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies

K. N. Cosgun, H. Jumaa, M. E. Robinson, X. Liang, G. Xiao, L. N. Chan, J. Lee, K. Kume, E. Leveille, D. Fonseca-Arce, D. Khanduja, H. L. Ng, N. Feldhahn, J. Song, W. C. Chan, , M. Mueschen

This study identifies a unique vulnerability in B-cell malignancies where GSK3β inhibitors disrupt β-catenin-Ikaros complexes, leading to MYC repression and cell death.

bioRxiv · Mar 13, 2023 · PreprintCancer Biology